CVE-2022-25852

Public Exploit
Denial of Service (DoS)

Description

All versions of package pg-native; all versions of package libpq are vulnerable to Denial of Service (DoS) when the addons attempt to cast the second argument to an array and fail. This happens for every non-array argument passed. **Note:** pg-native is a mere binding to npm's libpq library, which in turn has the addons and bindings to the actual C libpq library. This means that problems found in pg-native may transitively impact npm's libpq.

Category

7.5
CVSS
Severity: High
CVSS 3.1 •
CVSS 2.0 •
EPSS 0.09%
Third-Party Advisory snyk.io Third-Party Advisory snyk.io
Affected: n/a pg-native
Affected: n/a libpq
Published at:
Updated at:

References

Link Tags
https://snyk.io/vuln/SNYK-JS-PGNATIVE-2392365 third party advisory exploit
https://snyk.io/vuln/SNYK-JS-LIBPQ-2392366 third party advisory exploit

Frequently Asked Questions

What is the severity of CVE-2022-25852?
CVE-2022-25852 has been scored as a high severity vulnerability.
How to fix CVE-2022-25852?
To fix CVE-2022-25852, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2022-25852 being actively exploited in the wild?
It is possible that CVE-2022-25852 is being exploited or will be exploited in a near future based on public information. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2022-25852?
CVE-2022-25852 affects n/a pg-native, n/a libpq.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.